Societal CDMO, Inc. (SCTL)

Societal CDMO Reports Second Quarter 2022 Financial Results

Recorded Q2 Revenue of $23.2 Million, a 29% Increase Compared to Prior Year Period Signed Multiple New Business Agreements Spanning Clinical Trial Support, Commercial Manufacturing and Packaging Launched Innovative “20/80 Second Source Technical Transfer” Program; New Model Offers Increased Security and Flexibility to Customers Executed Favorable Amendment to Agreement with Lannett; Provides Improved Overall Economics to Societal Company to Host Webcast Today at 4:30 p.m. ET SAN DIEGO and GAINES

• 
  STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y

  Business Wire
• 
  Copperleaf Announces Second Quarter 2022 Results

  CNW Group

Societal CDMO Adds Three New Customers, Signing Agreements to Provide CDMO Services Supporting Clinical Development of Several Novel Therapeutic Candidates

Contracted Activities Touch Upon Broad Range of Societal’s Offerings from Clinical Trial Services to Formulation Development to cGMP Manufacturing Work to be Conducted Collaboratively at Societal’s East and West Coast Facilities SAN DIEGO and GAINESVILLE, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small mole

Societal CDMO to Report Financial Results for Second Quarter 2022 on August 10, 2022

Webcast Scheduled for Wednesday, August 10, 2022, at 4:30 p.m. EasternSAN DIEGO, Calif. and GAINESVILLE, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the second quarter 2022 after the marke